Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Gemcitabine Hydrochloride in Metastatic Triple-Negative Breast Carcinoma: NCT07528768 Clinical Landscape Report 2026
16 September 2026
NCT07528768 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Pomalidomide in Refractory Central Nervous System Lymphoma: NCT07523737 Clinical Landscape Report 2026
16 September 2026
NCT07523737 clinical landscape for Refractory Central Nervous System Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
RGT-490 in Locally Advanced Malignant Solid Neoplasm: NCT07524322 Clinical Landscape Report 2026
16 September 2026
NCT07524322 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Fludarabine Phosphate in Lupus Nephritis: NCT07523542 Clinical Landscape Report 2026
16 September 2026
NCT07523542 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HN-2302 in Scleroderma, Diffuse: NCT07523282 Clinical Landscape Report 2026
16 September 2026
NCT07523282 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RC-010 in Idiopathic Pulmonary Fibrosis: NCT07528703 Clinical Landscape Report 2026
16 September 2026
NCT07528703 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glofitamab in Diffuse Large B-Cell Lymphoma: NCT07528352 Clinical Landscape Report 2026
16 September 2026
NCT07528352 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inavolisib in Advanced Endometrial Carcinoma: NCT07522697 Clinical Landscape Report 2026
16 September 2026
NCT07522697 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belzupacap sarotalocan in Malignant melanoma of conjunctiva: ACTRN12626000465358 Clinical Landscape Report 2026
16 September 2026
ACTRN12626000465358 clinical landscape for Malignant melanoma of conjunctiva: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Fianlimab/Cemiplimab in Melanoma, Cutaneous Malignant: NCT07527325 Clinical Landscape Report 2026
16 September 2026
NCT07527325 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SCT-C21 in Systemic Lupus Erythematosus: NCT07538154 Clinical Landscape Report 2026
16 September 2026
NCT07538154 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nirogacestat hydrobromide in AIDS-related Kaposi Sarcoma: NCT07539454 Clinical Landscape Report 2026
16 September 2026
NCT07539454 clinical landscape for AIDS-related Kaposi Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.